H. Finnern

发表

Patients' preferences for treatment outcomes for advanced non-small cell lung cancer: a conjoint analysis.

John F P Bridges, A Brett Hauber, A. Hauber, 2012, Lung cancer.

Handling missing quality of life data in HIV clinical trials: what is practical?

A. Wu, D. Fairclough, H. Thijs, 2008, Quality of Life Research.

Collaboration between patient organisations and a clinical research sponsor in a rare disease condition: learnings from a community advisory board and best practice for future collaborations

R. Camp, F. Houÿez, W. Sauter, 2020, BMJ Open.

Cost-effectiveness of licensed treatment options for restless legs syndrome in the UK and Sweden

H. Finnern, M. Tabberer, M. Lees, 2008 .

What constitutes best supportive care in the treatment of advanced non-small cell lung cancer patients?--Results from the lung cancer economics and outcomes research (LUCEOR) study.

J. Vansteenkiste, C. Ziske, J. Lester, 2013, Lung cancer.

Cost-effectiveness of Tipranavir in Treatment-Experienced HIV Patients in the United States

K. Simpson, C. Hicks, H. Finnern, 2008, HIV clinical trials.

A. Wu, D. Fairclough, H. Thijs, 2008, Antiviral therapy.

Treatment patterns, use of resources, and costs of advanced non-small-cell lung cancer patients in Spain: results from a Delphi panel

D. Isla, M. Brosa, H. Finnern, 2011, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

A cross-country review of data collected on non-small cell lung cancer (NSCLC) patients in cancer registries, databases, retrospective and non-randomized prospective studies

A. De Geer, H. Finnern, J. Eriksson, 2013, Journal of medical economics.

Meta-analysis of the efficacy and tolerability of pramipexole versus ropinirole in the treatment of restless legs syndrome.

K. Abrams, A. Nicolas, S. Quilici, 2008, Sleep medicine.

J. Vansteenkiste, J. Lester, C. Chouaid, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Symptom and Quality of Life Benefit of Afatinib in Advanced Non–Small-Cell Lung Cancer Patients Previously Treated with Erlotinib or Gefitinib: Results of a Randomized Phase IIb/III Trial (LUX-Lung 1)

D. Fairclough, V. Miller, J. Yang, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

The hospital cost of vertebral fractures in the EU: estimates using national datasets

D. Sykes, H. Finnern, 2003, Osteoporosis International.

Burden of illness imposed by severe sepsis in Switzerland.

S. Marsch, J. Chevrolet, J. Pugin, 2004, Swiss medical weekly.

Treatment of lung cancer patients and concomitant use of drugs interacting with cytochrome P450 isoenzymes.

R. Kaiser, M. Eichelbaum, H. Varker, 2011, Lung cancer.

Cost Effectiveness and Resource Allocation Cost-effectiveness of Tipranavir versus Comparator Protease Inhibitor Regimens in Hiv Infected Patients Previously Exposed to Antiretroviral Therapy in the Netherlands

M. Postma, K. Simpson, G. Hubben, 2007 .

Patterns of treatment for restless legs syndrome in primary care in the United Kingdom.

C. Martinez, K. Chaudhuri, A. Schapira, 2008, Clinical therapeutics.